Investor Overview Press Releases March 15, 2021 Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis February 25, 2021 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update February 22, 2021 Aclaris Therapeutics to Participate in Upcoming Investor Conferences View all » Events Mar 16, 202110:00 AM EDT Aclaris Therapeutics, Inc. at Oppenheimer 31st Annual Healthcare Conference Mar 9, 20217:00 AM EST Aclaris Therapeutics, Inc. at H.C. Wainwright Global Life Sciences Conference Feb 25, 20218:00 AM EST Aclaris Therapeutics, Inc. at 10th Annual SVB Leerink Global Healthcare Conference View all » Feature Presentation Aclaris Therapeutics Company Overview - March 2021
March 15, 2021 Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
February 25, 2021 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Feb 25, 20218:00 AM EST Aclaris Therapeutics, Inc. at 10th Annual SVB Leerink Global Healthcare Conference